Navigation Links
MicroRNA that could be used to suppress prostate cancer progression found

CINCINNATIAbout one in seven men will develop prostate cancer over the course of a lifetime, and about one in 36 men will die from it.

This is why findings by Cincinnati Cancer Center researchers, showing that a tumor suppressive microRNA, when activated by an anti-estrogen drug, could contribute to development of future targeted therapies, are important.

These findings are published in the May 16, 2014 edition of the journal PLOS ONE.

"MicroRNAs, or miRNAs, are short RNA molecules that play a prominent role in regulating gene expression. One miRNA can target multiple genes, but their expression is often hijacked by cancer cells and disrupts multiple cancer-causing or tumor-suppressing pathways," says Shuk-Mei Ho, PhD, director of the CCC and Jacob G. Schmidlapp Chair of Environmental Health and professor at the University of Cincinnati (UC) College of Medicine.

She along with Ricky Y.K. Leung, PhD, member of the CCC, assistant research professor in the department of environmental health and member of the UC Cancer Institute, and their team identified a new miRNA, known as hsa-miR-765, which is specifically activated by a Food and Drug Administration (FDA)-approved anti-estrogen drug (fulvestrant).

"This miRNA suppresses expression of HMGA1, a gene that was shown in previous studies to be associated with prostate cancer progression and recurrence," says Leung. "These findings do not only contribute to new insights on the effects of anti-estrogen but also the potential of using miRNA for monitoring drug efficacy and for future RNA-based therapy developments.

"This study also highlights the potential use of this anti-estrogen or miRNA in patients with recurrent prostate cancer, for whom there is no treatment, and raises the possibility of using anti-estrogen or miRNA treatments in preventing or slowing progression for primary prostate cancer."

Using cultured prostate cancer specimens from patients who were given a single 250 mg dose of fulvestrant, researchers found that hsa-miR-765 acted as a tumor suppressor when its expression was increased by the use of fulvestrant.

"Both the anti-estrogen and the hsa-miR-765 mimic suppressed HMGA1 protein expression," Ho says. "Levels of hsa-miR-765 were increased, and HMGA1 expression was almost completely lost in prostate cancer specimens from patients treated with a single dose of fulvestrant 28 days before removal of their prostate glands.

"These findings reveal a unique fulvestrant signaling process involving the increased regulation of hsa-miR-765 that suppresses the HMGA1 protein as part of the mechanism underlying the tumor suppressor action in prostate cancer. This could lead to newer treatment options with less toxicity for these patients."

Contact: Katie Pence
University of Cincinnati Academic Health Center

Related medicine news :

1. MicroRNA could be key target for bowel cancer treatment
2. Fruit fly microRNA research at Rutgers-Camden offers clues to aging process
3. Viral microRNAs responsible for causing AIDS-related cancer, new USC study shows
4. Wayne State to study role of microRNAs in prostate cancer racial disparities
5. MicroRNA-31 might predict lung-cancer spread
6. Versatile microRNAs choke off cancer blood supply, suppress metastasis
7. Loss of MicroRNA decoy might contribute to development of soft-tissue sarcoma
8. New papers identify a microRNA that drives both cancer onset and metastasis
9. Moffitt Cancer Center researchers say 1 specific microrna promotes tumor growth and cancer spread
10. Atherosclerosis: Specific microRNAs promote inflammation
11. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... of a new PDF automation tool to batch conversions of CAD drawings, ... with 100% document fidelity. , CADConverter eliminates the complexity requirement of specialized applications ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... and development solutions for drugs, biologics, consumer health and animal health products, today ... and will lead a new, dedicated global team of drug development and technology ...
(Date:10/12/2015)... ... October 13, 2015 , ... North American Tool Corporation has ... 2015 IBC National Meeting in Rosemont, IL on October 4th. , ... standards of excellence that customers have come to expect from members of IBC’s marketing ...
(Date:10/12/2015)... ... , ... Amerec , a leader in the steam and sauna industry, ... be displaying custom sauna and steam room solutions at the ISPA Conference & Expo ... customers, SpaEquip is recognized for their ability to assist in the design and implementation ...
(Date:10/12/2015)... AL (PRWEB) , ... October 12, 2015 , ... American ... continues to expand its footprint by opening its 151st medical center. Located at 606A ... , “We’re excited to continue fulfilling our mission of making quality health care ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Asterias Biotherapeutics, ... with the UK-based Cell Therapy Catapult to advance ... Asterias, allogeneic dendritic cell immunotherapy. Under the agreement, ... manufacturing processes for AST-VAC2 to support advanced clinical ... --> --> The Cell ...
(Date:10/12/2015)... , Oct. 12, 2015 Given ... it is quite challenging to deliver an ophthalmic drug effectively ... overcome for a successful ocular drug delivery. These include dilution ... the lymphatic system of conjunctiva and drug permeation issues with ... the drug, in topical eye drops, is lost due to ...
(Date:10/12/2015)... Use this report to: - Learn about ... medical membrane devices market. - Analyze the present and ... membrane devices market including hemodialyzers, membrane oxygenators, intravenous infusion ... - Gain information on newly approved products, recalls and ... this report to: - Learn about the performance, the ...
Breaking Medicine Technology: